Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
|
Add to portfolio |
|
|
|
| Price: |
$63.93
| | Metrics |
| OS: |
107.2
|
M
| |
|
|
| Market cap: |
$6.85
|
B
| |
|
|
|
Net cash:
|
$494
|
M
| |
$4.61
|
per share
|
|
EV:
|
$6.36
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($147)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 243.2 | 138.3 | 88.0 | 168.8 | 16.1 | 31.4 | 0.2 | 0.4 |
| Revenue growth | 75.9% | 57.2% | -47.9% | 945.7% | -48.6% | 19736.5% | -58.6% | 118.3% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -87.8 | 16.6 |
| Gross profit | 243.2 | 138.3 | 88.0 | 168.8 | 16.1 | 31.4 | 87.9 | -16.2 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 55529.7% | -4233.5% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 297.3 | 206.3 | 128.9 | 81.0 | 53.0 | 50.9 | 62.1 | 47.3 |
| General and administrative | 124.4 | 81.0 | 52.3 | 26.6 | 19.1 | 17.5 | 23.6 | 7.9 |
| EBITA | -176.8 | -147.3 | -91.5 | 62.9 | -54.2 | -35.3 | -83.8 | -93.0 |
| EBITA margin | -72.7% | -106.5% | -103.9% | 37.3% | -336.0% | -112.4% | -52951.7% | -24349.9% |
| Amortization of intangibles | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.0 |
| EBIT | -178.5 | -149.0 | -93.2 | 61.2 | -55.9 | -37.0 | -85.6 | -94.1 |
| EBIT margin | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% | -117.8% | -54034.5% | -24623.9% |
| Pre-tax income | -172.7 | -140.8 | -84.6 | 68.1 | -54.4 | -34.4 | -81.7 | -91.9 |
| Income taxes | 3.8 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.3% | | | | |
| Net income | -176.1 | -140.8 | -84.6 | 68.0 | -54.5 | -34.4 | -81.7 | -91.9 |
| Net margin | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% | -109.5% | -51614.6% | -24068.3% |
| |
| Diluted EPS | ($1.67) | ($1.36) | ($0.84) | $0.69 | ($0.65) | ($0.47) | ($1.34) | ($1.60) |
| Shares outstanding (diluted) | 105.4 | 103.7 | 100.7 | 98.6 | 83.6 | 73.9 | 61.1 | 57.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|